RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE

Mirum Pharmaceuticals Stocks 2024

Mirum Pharmaceuticals Stocks

40.89 M

Mirum Pharmaceuticals Dividend yield

Ticker

MIRM

ISIN

US6047491013

WKN

A2PM29

In 2024, Mirum Pharmaceuticals had 40.89 M outstanding stocks, a 0% change from the 40.89 M stocks in the previous year.

The Mirum Pharmaceuticals Stocks history

YEARNUMBER OF STOCKS (undefined USD)
2030e40.89
2029e40.89
2028e40.89
2027e40.89
2026e40.89
2025e40.89
2024e40.89
202340.89
202233.84
202130.32
202025.25
201923.02
201823.02

Mirum Pharmaceuticals Aktienanalyse

What does Mirum Pharmaceuticals do?

Mirum Pharmaceuticals Inc is a biopharmaceutical company that specializes in the development and marketing of therapeutics for rare intestinal diseases. The company was founded in 2018 in California, USA and has experienced rapid growth since then. The company was founded after an unusual event in 2015 when Shire Pharmaceuticals plc, a large British pharmaceutical company, acquired the biotech company Lumena Pharmaceuticals Inc. The management of Lumena discovered a compound that they believed could relieve cholestasis, a condition where bile cannot flow adequately and therefore remains in the liver. They realized that this compound, if modified and used in a new formulation, could also be used to treat other rare intestinal diseases. The management of Lumena decided to pursue this idea and thus founded Mirum Pharmaceuticals Inc. The company's business model is to develop novel medications for the treatment of severe and rare intestinal diseases through a combination of in-house research and external collaborations. Mirum Pharmaceuticals Inc aims to fill a niche focusing on smaller patient populations that are often overlooked by larger pharmaceutical companies due to their rarity. The company also aims to work closely with patients and their families to ensure that their needs and concerns are incorporated into their product development processes. Currently, Mirum Pharmaceuticals Inc's research and development efforts focus on two main areas: cholestasis and intestinal enteropathies. Cholestasis is a condition where the liver is unable to secrete bile into the intestine, resulting in the accumulation of bile in the body and damage to liver cells and other organs. Mirum Pharmaceuticals Inc is currently developing Maralixibat, a medication targeting the treatment of intrahepatic cholestasis in children. Intestinal enteropathies are rare intestinal diseases characterized by a disruption of the intestinal tract. Mirum Pharmaceuticals Inc is dedicated to researching and developing a medication for the treatment of PFIC, a rare condition where bile fluid is no longer adequately excreted. In this regard, the company has entered into an agreement with Dova Pharmaceuticals Inc., which was acquired by Merck&Co. in mid-2019. Under this agreement, Mirum Pharmaceuticals Inc acquired the rights to a medication for the treatment of PFIC developed by Dova. Mirum Pharmaceuticals solutions aim to treat patients on a relevant basis and provide support for families and caregivers of patients. In summary, Mirum Pharmaceuticals Inc is a biopharmaceutical company that emerged from a spin-out of Lumena Pharmaceuticals Inc from Shire. It has focused on the development of therapeutics for rare intestinal diseases and works closely with patients and their families to ensure their concerns are considered in product development processes. The product research of Mirum Pharmaceuticals Inc currently focuses on Maralixibat, a medication for the treatment of intrahepatic cholestasis, as well as Mirum Pharmaceuticals Inc, a medication for the treatment of PFIC. Mirum Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Stocks Details

Evaluating Mirum Pharmaceuticals's Shares Outstanding

Mirum Pharmaceuticals's shares outstanding refer to the total number of shares that are currently held by all its shareholders, including institutional investors and restricted shares held by the company’s officers and insiders. The number of shares outstanding is crucial in determining the company's market capitalization and is used by investors to assess the company’s size, financial health, and investment potential.

Year-to-Year Comparison

Tracking the changes in Mirum Pharmaceuticals’s shares outstanding over the years can provide investors with insights into the company's financial strategies and market valuation. An increase in shares outstanding can result from actions like issuing new shares, while a decrease can result from buybacks.

Impact on Investments

For investors, understanding Mirum Pharmaceuticals’s shares outstanding is essential for evaluating its earnings per share (EPS) and market valuation. A change in the number of shares outstanding can impact the EPS, which is a significant driver of stock prices and investor decisions.

Interpreting Changes in Shares Outstanding

Variances in Mirum Pharmaceuticals’s shares outstanding can signal shifts in the company’s financial strategy. An increase may dilute the EPS and share value, indicating potential fundraising or acquisitions. Conversely, a decrease, often due to share buybacks, can enhance share value and indicate the company’s confidence in its financial performance.

Frequently Asked Questions about Mirum Pharmaceuticals Stock

How many stocks are there of Mirum Pharmaceuticals?

The current number of stocks of Mirum Pharmaceuticals is 40.89 M undefined.

What does Number of Shares / OutstandingShares mean?

The outstanding shares (or issued shares) of Mirum Pharmaceuticals are the total number of shares issued and actively held by shareholders - both external investors and company insiders. However, these must be actual shares. may grant stock options to executives that can be converted into shares.

How has the number of shares of Mirum Pharmaceuticals evolved in recent years?

The number of shares of Mirum Pharmaceuticals has increased by 0% gestiegen compared to last year.

What does the number of shares mean for investors?

The number of shares outstanding is used to calculate key metrics such as a company's market capitalization, earnings per share (EPS), and cash flow per share (CFPS). The number of outstanding shares of a company is not static and can fluctuate greatly over time.

Why does the number of stocks fluctuate?

There are various factors that can lead to a change. Mirum Pharmaceuticals as a company can issue new shares, carry out stock splits or reverse splits.

Does the number of shares have an impact on the performance of Mirum Pharmaceuticals?

There is no tangible long-term evidence or study that stocks with a certain number of shares (regardless of Mega/Large/Mid/Small Cap) would yield significantly higher returns than others. There are occasional small studies (limited number of stocks, short investment period) that certain classes outperform or have higher risk, but none of them are 1. conclusive (cause-effect is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).

How much dividend does Mirum Pharmaceuticals pay?

Over the past 12 months, Mirum Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Mirum Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Mirum Pharmaceuticals?

The current dividend yield of Mirum Pharmaceuticals is .

When does Mirum Pharmaceuticals pay dividends?

Mirum Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Mirum Pharmaceuticals?

Mirum Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Mirum Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Mirum Pharmaceuticals located?

Mirum Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Mirum Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Mirum Pharmaceuticals from 6/3/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 6/3/2024.

When did Mirum Pharmaceuticals pay the last dividend?

The last dividend was paid out on 6/3/2024.

What was the dividend of Mirum Pharmaceuticals in the year 2023?

In the year 2023, Mirum Pharmaceuticals distributed 0 USD as dividends.

In which currency does Mirum Pharmaceuticals pay out the dividend?

The dividends of Mirum Pharmaceuticals are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Mirum Pharmaceuticals

Our stock analysis for Mirum Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Mirum Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.